The European Medicines Agency (EMA) approved mavacamten in June 2023 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials have demonstrated its efficacy in improving exercise capacity, reducing the left ventricular outflow tract (LVOT) gradient, and alleviating symptoms, and decreases the need for invasive septal reduction therapies.

Pharmacogenetic testing to broaden patient eligibility for mavacamten / Van der Linden L., Van Aelst L., Olivotto I.. - In: EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY. - ISSN 2055-6837. - ELETTRONICO. - 11:(2025), pp. 92-93. [10.1093/ehjcvp/pvae086]

Pharmacogenetic testing to broaden patient eligibility for mavacamten

Olivotto I.
2025

Abstract

The European Medicines Agency (EMA) approved mavacamten in June 2023 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials have demonstrated its efficacy in improving exercise capacity, reducing the left ventricular outflow tract (LVOT) gradient, and alleviating symptoms, and decreases the need for invasive septal reduction therapies.
2025
11
92
93
Goal 3: Good health and well-being
Van der Linden L.; Van Aelst L.; Olivotto I.
1a - Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1499530
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact